These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 35411416)
1. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy. Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416 [TBL] [Abstract][Full Text] [Related]
2. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy. Sun J; Cheng M; Ye T; Li B; Wei Y; Zheng H; Zheng H; Zhou M; Piao JG; Li F Nanomedicine (Lond); 2022 Nov; 17(26):2037-2054. PubMed ID: 36789952 [TBL] [Abstract][Full Text] [Related]
3. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633 [TBL] [Abstract][Full Text] [Related]
4. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma. Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495 [TBL] [Abstract][Full Text] [Related]
5. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma. Liu J; Li X; Chen J; Zhang X; Guo J; Gu J; Mei C; Xiao Y; Peng C; Liu J; Hu X; Zhang K; Li D; Zhou B ACS Appl Mater Interfaces; 2023 Feb; 15(5):6260-6273. PubMed ID: 36695492 [TBL] [Abstract][Full Text] [Related]
6. ZnAs@SiO Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768 [No Abstract] [Full Text] [Related]
7. MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma. Li C; Zhang K; Liu A; Yue T; Wei Y; Zheng H; Piao JG; Li F Int J Pharm; 2021 Nov; 609():121209. PubMed ID: 34678398 [TBL] [Abstract][Full Text] [Related]
8. PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy. Jiang L; Wang X; Raza F; Zhong H; Su J; Yuan WE; Qiu M Biomater Sci; 2023 Jul; 11(15):5301-5319. PubMed ID: 37357799 [TBL] [Abstract][Full Text] [Related]
9. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Kong D; Jiang T; Liu J; Jiang X; Liu B; Lou C; Zhao B; Carroll SL; Feng G Drug Deliv; 2020 Nov; 27(1):1729-1740. PubMed ID: 33307843 [TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cai X; Yu L; Chen Z; Ye F; Ren Z; Jin P Cancer Biomark; 2020; 28(2):221-230. PubMed ID: 32280078 [TBL] [Abstract][Full Text] [Related]
11. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo. Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700 [TBL] [Abstract][Full Text] [Related]
12. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma. Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794 [TBL] [Abstract][Full Text] [Related]
13. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma. Chi X; Zhang R; Zhao T; Gong X; Wei R; Yin Z; Lin H; Li D; Shan H; Gao J Nanotechnology; 2019 Apr; 30(17):175101. PubMed ID: 30654348 [TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405 [TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma. Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648 [TBL] [Abstract][Full Text] [Related]
16. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells. Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461 [TBL] [Abstract][Full Text] [Related]
17. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070 [TBL] [Abstract][Full Text] [Related]
18. Liposome-Coated Arsenic-Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma. Jin Z; Yi X; Yang J; Zhou M; Wu P; Yan G Int J Nanomedicine; 2021; 16():3775-3788. PubMed ID: 34113100 [TBL] [Abstract][Full Text] [Related]
19. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo. Xiao X; Liu Y; Guo M; Fei W; Zheng H; Zhang R; Zhang Y; Wei Y; Zheng G; Li F J Biomater Appl; 2016 Jul; 31(1):23-35. PubMed ID: 27059495 [TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Zhang X; Hu B; Sun YF; Huang XW; Cheng JW; Huang A; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J; Yang XR Clin Transl Med; 2021 Feb; 11(2):e335. PubMed ID: 33634982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]